Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

THE TRUTH ABOUT: 35 - Caught on Camera

Revealed: UK government was warned of infected blood risks in 1970s

Documents show officials were told blood plasma harvested from US convicts was contaminated with viruses

The Guardian - UK

‘Plasma was called liquid gold’: the true story of the UK infected blood scandal

Documents examined by inquiry show officials knew people were being given infected blood products, but sanctioned their use

The Guardian - UK

AstraZeneca's £18.7m boss Soriot bounces back as pharma giant reveals 18% sales growth

Soriot came under fire this month for his £18.7 million pay packet

Evening Standard

From analysis to the latest developments in health,
read the most diverse news in one place.

Experts warn of influx of synthetic opioids amid calls for second Melbourne injecting room

Use of deadly nitazines is on the rise in Australia and a suite of measures is needed to prevent more fatalities, former New Zealand prime minister Helen Clark says

The Guardian - AU

People with MND in England and Wales fear losing access to life-extending drug

NHS cost threshold has not been raised by National Institute for Health and Care Excellence since 2004

The Guardian - UK

Exploring The Powerful Benefits Of Natural Health Products Made With Cutting-Edge Science

In a post-COVID world, society is branching away from pharmaceutical medicine and seeking support that may be less likely to cause side effects.

International Business Times

JNJ Earnings Forecast - Is Pharmaceutical Industry Set for Shake-up?

As pharma titan Johnson & Johnson (JNJ) gears up to unveil its first-quarter results on April 16, 2024, anticipation looms over the pharmaceutical industry. JNJ’s recent acquisitions signal the company’s strategic expansions, and given its history as one of the prominent pharma companies, is JNJ’s forecast as stunning? Let us…

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

The danger in saying yes to Pascal Soriot’s pay rise at AstraZeneca

Despite rebellion, approval of £18.7m package opens door to likelihood of US-style executive pay elsewhere

The Guardian - UK

Unbiased Friday Plans Reviews—Who Should Get Friday Plans Viagra And Cialis?

Friday Plans has a stellar 4.3-star rating on Trustpilot, with 40,000+ subscribers praising the convenience, speed, affordability, and effectiveness of their Viagra and Cialis products.

International Business Times

AstraZeneca CEO’s £18.7m pay approved despite shareholder rebellion

Third of voters reject Pascal Soriot’s deal but some say it is deserved as he had been ‘massively underpaid’

The Guardian - UK

3 Pharma Stocks Delivering Exciting April Returns

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs, increasing demand for innovative medications, and technological advancements. Therefore, fundamentally strong pharmaceutical stocks Dr. Reddy’s (RDY), Teva Pharmaceutical Industries (TEVA), and AbbVie (ABBV) could be worth adding to your portfolio. Read on.

StockNews.com

3 Biotech Gems Poised for April Breakthroughs

The biotechnology industry is expected to grow rapidly due to rising demand for personalized medicines, increased R&D spending, and the adoption of AI in the biopharma market. Hence, quality biotech stocks Incyte (INCY), Jazz Pharmaceuticals (JAZZ), and Exelixis (EXEL) could be poised for breakthroughs this month. Read more….

StockNews.com

3 A-Rated Pharma Stocks to Boost Your Bottom Line

The pharmaceutical industry is experiencing rapid growth thanks to healthcare demand, regulatory initiatives, and technological adoption in drug discovery and development. Hence, it could be wise to invest in pharma stocks Ipsen (IPSEY), Bristol-Myers (BMY), and Taro Pharmaceutical (TARO) to drive your bottom line. These stocks are rated A (Strong…

StockNews.com

4 Pharma Giants Sparking Investor Interest

The pharmaceutical industry is growing steadily, focusing more on technological innovation, precision medicine, and strategic mergers and acquisitions (M&A). So, let’s take a look at pharma giants Novo Nordisk A/S (NVO), Johnson & Johnson (JNJ), Merck & Co. (MRK), and AbbVie (ABBV) igniting investor interest. Keep reading….

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

StockNews.com

3 Lucrative Pharma Stocks to Diversify Your Investments

The pharma industry’s resilience and long-term prospects are driven by rising healthcare demand, an enhanced focus on precision medicines, and technological advancements. Hence, let’s take a look at pharma stocks Perrigo Company (PRGO), Amneal Pharmaceuticals (AMRX), and Supernus Pharmaceuticals (SUPN), which could diversify your investments. Read on….

StockNews.com

Canopy Growth (CGC) vs. Novo Nordisk (NVO): Which Pharma Stock Is a Better Investment?

The Pharma sector’s innovative trial methodologies and shift toward customized medicine signal transformative growth potential in the pharmaceutical industry. While leading Pharma stocks Canopy Growth (CGC) and Novo Nordisk (NVO) stand to benefit, let us analyze which of them is a better investment.

StockNews.com

Aurora Cannabis (ACB) vs. Merck (MRK): Which Pharma Stock Holds Greater Potential for Investors?

The pharmaceutical industry is poised for robust growth owing to technological advancements and growing healthcare needs. Given this backdrop, let’s analyze Aurora Cannabis (ACB) and Merck & Co. (MRK) to determine which of the two stocks holds greater potential for investors. Read on….

The Guardian - UK

Cheaper private Covid jabs may end up as costly as pricier ones, say experts

Exclusive: Multi-dose vials could push up charge per patient, with experts warning cost could widen inequalities

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

NPPA revises ceiling prices of over 800 scheduled drug formulations from April 1

Cost of antibiotics and painkillers have registered a marginal hike in cost starting with the drug price regulator National Pharmaceutical Pricing Authority’s latest notification

Reason

Drug Company's Libel Lawsuit Against Scientists Dismissed

From yesterday's decision by Judge Gregory Woods (S.D.N.Y.) in Cassava Sciences, Inc. v. Bredt: Cassava Sciences, Inc. ("Cassava") is a biotechnology company that is conducting clinical trials for an Alzheimer's drug called simufilam. Following the second phase of the simufilam clinical trials, multiple short sellers, most of them scientists, published…

The Guardian - UK

Nearly 1,000 pharmacies in England closed since 2017, with poorer areas more affected

Exclusive: Millions more GP appointments potentially created as a result of closures

Kiplinger

New List Out On Medicare Part B Drugs Eligible for Rebates

Some Medicare beneficiaries may pay lower coinsurance rates from April 1 to June 30 for the drugs, HHS says.

Salon

19th Century law versus bodily autonomy

Abortion opponents are citing the Comstock Act to stop "abortion pill trafficking." Experts say that's nonsense

Evening Standard

'Everywhere I look private companies are more valuable': Biotech firm C4X becomes latest to quit London stock market

Biotech firm C4X today became the latest business to abandon the London stock market after is said its future growth would be better secured through private investment.

France 24

US Supreme Court hears arguments in abortion pill case

U.S. Supreme Court justices on Tuesday did not appear ready to limit access to the abortion pill mifepristone, in a case that could have far-reaching implications for millions of American women and for scores of drugs regulated by the Food and Drug Administration.

1 … 34 35 36 37

People

Clarence Thomas

1,477 stories

Ketanji Brown Jackson

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.